Mitochondrial respiratory chain component NDUFA4: a promising therapeutic target for gastrointestinal cancer

Quanling Zhou1,2, Xiaohui Li2, Honglian Zhou2

  • 1Department of Pathophysiology, Zunyi Medical University, Zunyi, 563000, Guizhou, China.

PubMed

Insights

Altered mitochondrial metabolism involving NADH dehydrogenase 1 alpha subcomplex 4 (NDUFA4) impacts gastrointestinal cancer. Understanding NDUFA4

Area of Science:

  • Biochemistry and Molecular Biology
  • Oncology
  • Mitochondrial Biology

Background:

  • Gastrointestinal cancers are leading causes of global mortality.
  • Mitochondrial energy metabolism is increasingly recognized in disease pathogenesis.
  • NDUFA4, a component of mitochondrial respiratory chain complex IV, is crucial for energy metabolism.

Purpose of the Study:

  • To comprehensively review the structure, regulation, and function of NDUFA4.
  • To explore the role of NDUFA4 in the pathogenesis of gastrointestinal cancers.
  • To discuss NDUFA4 as a potential therapeutic target for gastrointestinal cancer intervention.

Main Methods:

  • Literature review of existing research on NDUFA4.
  • Analysis of NDUFA4 expression and its correlation with gastrointestinal cancer.
  • Discussion of NDUFA4's regulatory mechanisms and biological functions in cancer.

Main Results:

  • NDUFA4 plays a significant role in mitochondrial energy metabolism.
  • Aberrant NDUFA4 expression is linked to the development and progression of gastrointestinal cancers.
  • NDUFA4 influences cancer cell growth and metastasis.

Conclusions:

  • NDUFA4 is implicated in the pathogenesis of various gastrointestinal cancers, including colorectal, liver, and gastric cancers.
  • NDUFA4 represents a promising novel target for gastrointestinal cancer intervention.
  • Further research into NDUFA4-based strategies is needed for clinical application.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
169
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K